GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » 3-Year EPS without NRI Growth Rate

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) 3-Year EPS without NRI Growth Rate : 0.10% (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) 3-Year EPS without NRI Growth Rate?

Dawnrays Pharmaceutical (Holdings)'s EPS without NRI for the six months ended in Dec. 2024 was HK$0.08.

During the past 12 months, Dawnrays Pharmaceutical (Holdings)'s average EPS without NRI Growth Rate was 2.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 0.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Dawnrays Pharmaceutical (Holdings) was 36.70% per year. The lowest was -17.50% per year. And the median was 6.00% per year.


Competitive Comparison of Dawnrays Pharmaceutical (Holdings)'s 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Dawnrays Pharmaceutical (Holdings)'s 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dawnrays Pharmaceutical (Holdings)'s 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dawnrays Pharmaceutical (Holdings)'s 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Dawnrays Pharmaceutical (Holdings)'s 3-Year EPS without NRI Growth Rate falls into.


;
;

Dawnrays Pharmaceutical (Holdings) 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Dawnrays Pharmaceutical (Holdings) 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Li Kei Ling
Hung Yung Lai
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines